Recent price: 1.74$P/E Ratio: -3 months Target Price: 2.25$
Company DescriptionVical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery...
Follow through to the website for more complete reports
Vical Inc. (NASDAQ: VICL) tumbled as much as 40% after partner Sanofi-Aventis (NYSE: SNY) announced that late stage trials of NV1FGF failed to meet its goal of preventing limb amputation or...(read more
Vical Inc (NASDAQ: VICL) dipped 34.97% to $2.51 in the pre-market session. VICL's quarterly revenue dipped 47.84% y/y.
Adobe Systems Inc (NASDAQ: ADBE) lost 21.13% to $25.98 in the pre-market session. ADBE has projected...(read more